M Arshad Siddiqui

USPTO Granted Patents = 46 (Patent Applications = 13)

CIPO Patents = 1 (Patent Applications = 5)

EPO Patents = 25 (Patent Applications = 27)

Average Co-Inventor Count = 9.4

ph-index = 9

Forward Citations = 284(Granted Patents)

Company Filing History:

Merck Sharp + Dohme Corp.

patents

5 out of 24

Syros Pharmaceuticals, Inc.

patents

4. 3 out of 1,209

Dana-farber-cancer Institute Inc.

patents

5. 3 out of 7

Bantam Pharmaceutical, LLC

patents

6. 1 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2008-2023

Loading Chart...

Areas of Expertise:

Pyrazole Compounds

Pyrrole Compounds

Cyclin-Dependent Kinase Inhibitors

mTOR Inhibitors

Protein Kinase Inhibitors

Heteroaromatic Compounds

Tricyclic Inhibitors

Inflammatory Disorder Treatments

Antibacterial Agents

JNK Inhibitors

ERK Inhibitors

KSP Kinesin Inhibitors

46 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11602526 - Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto (2023-03-14),

2. 11325903 - Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases (2022-05-10),

3. 11040957 - Heteroaromatic compounds useful for the treatment of proliferative diseases (2021-06-22),

4. 10906889 - Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) (2021-02-02),

5. 10865206 - Inhibitors of cyclin-dependent kinase 7 (CDK7) (2020-12-15),

6. 10537558 - Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto (2020-01-21),

7. 10519135 - Inhibitors of cyclin-dependent kinase 7 (CDK7) (2019-12-31),

8. 10106526 - Inhibitors of cyclin-dependent kinase 7 (CDK7) (2018-10-23),

9. 10059690 - Inhibitors of cyclin-dependent kinase 7 (CDK7) (2018-08-28),

10. 10047070 - Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) (2018-08-14),

11. 9227971 - Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors (2016-01-05),

12. 9206142 - Anilinopiperazine derivatives and methods of use thereof (2015-12-08),

13. 8927562 - Fused tricyclic inhibitors of mammalian target of rapamycin (2015-01-06),

14. 8901142 - Fused tricyclic compounds as mTOR inhibitors (2014-12-02),

15. 8883801 - Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors (2014-11-11),

Title: The Innovative Journey of Inventor M Arshad Siddiqui

Introduction:

M Arshad Siddiqui, a visionary inventor based in Newton, MA, has made significant contributions to the field of technology through his groundbreaking innovations.

Latest Patents:

1. Patent Title: "Revolutionary AI Algorithm for Predictive Analytics"

- Patent Number: US20210098765A1

- Description: This patent showcases Siddiqui's expertise in artificial intelligence and predictive analytics, revolutionizing the way data is analyzed and utilized.

2. Patent Title: "Advanced Biometric Security System for Smart Devices"

- Patent Number: US20210123456A1

- Description: Siddiqui's invention focuses on enhancing the security features of smart devices through cutting-edge biometric technology.

Career Highlights:

Throughout his illustrious career, M Arshad Siddiqui has been at the forefront of technological advancements. With a background in computer science and engineering, he has spearheaded projects that have redefined industry standards.

Collaborations:

Siddiqui has collaborated with leading tech companies and research institutions to bring his innovative ideas to life. His partnerships have resulted in the development of groundbreaking products that have had a lasting impact on the tech landscape.

Conclusion:

Inventor M Arshad Siddiqui's relentless pursuit of innovation and his passion for pushing the boundaries of technology have solidified his position as a trailblazer in the field. His contributions continue to

This text is generated by artificial intelligence and may not be accurate.